Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

Published:2018-09-04 Issue:1 Volume:20 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Buus Richard^ORCID,Yeo Belinda,Brentnall Adam R.,Klintman Marie,Cheang Maggie Chon U.,Khabra Komel,Sestak Ivana,Gao Qiong,Cuzick Jack,Dowsett Mitch

Funder

Breast Cancer Now

Cancer Research UK

NIHR RM/ICR Biomedical Research Centre

Skåne County Council’s Research and Development Foundation

Governmental Funding of Clinical Research within the National Health Service

Swedish Breast Cancer Association

Fru Berta Kamprads Stiftelse

The Inger Persson Research Foundation

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-018-1040-9.pdf

Reference30 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

2. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

3. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.

4. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008;14(9):2601–8.

5. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012–20.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays;Journal of Surgical Oncology;2024-06-24

2. XGBoost-based and tumor-immune characterized gene signature for the prediction of metastatic status in breast cancer;Journal of Translational Medicine;2022-04-18

3. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy;Biochemical Pharmacology;2021-07

4. The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives;Seminars in Cancer Biology;2020-12

5. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years;Breast Cancer Research;2020-09-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3